Introduction and Importance: Colorectal adenocarcinoma typically metastasizes to the liver and lungs, with pleural, breast, or osseous involvement being exceedingly rare. Here, we report an unusual case of rectal adenocarcinoma metastasizing to the chest wall with simultaneous involvement of the lung, pleura, ribs, and subcutaneous breast tissue, forming a dominant giant metastasis (25 × 18 × 16 cm) accompanied by additional satellite lesions between the ribs and pectoral muscles, as well as intrapulmonary nodules. Presentation of case: The patient underwent radical resection including rib excision, followed by hyperthermic intrathoracic chemotherapy (HITHOC) with mitomycin. Chest wall integrity was restored using a synthetic mesh and titanium plating, ensuring both oncologic clearance and structural stability. Multimodal therapy also included neoadjuvant chemotherapy with bevacizumab, which was continued postoperatively. Clinical discussion: This case underscores the critical role of a multidisciplinary strategy in managing rare and aggressive metastatic patterns of colorectal cancer. In selected patients, a combination of systemic therapy, extensive surgical resection, advanced reconstruction, and regional chemotherapy may offer the potential for short-term local disease control. Conclusions: The radical excision of the giant tumour enabled continuation of systemic therapy under the national drug programme, was associated with short-term local control, and improved the patient’s quality of life.

Purpose: Benign thyroid diseases are common conditions that often require long-term treatment. In some patients, symptoms persist despite normalization of biochemical parameters, significantly affecting quality of life (QoL). This study evaluated treatment-associated changes in QoL using the thyroid patient reported outcome (ThyPRO) questionnaire and summarized differences in QoL profiles reported across thyroid conditions. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. PubMed, Scopus, and Embase were searched up to April 2024. Data were extracted and synthesized using standardized mean differences. Results: Twenty-five studies were included. Significant pre-post-treatment improvements in overall QoL and selected symptom domains were observed. In Graves’ disease, improvements were observed in hyperthyroid symptoms, anxiety, impaired daily life, and overall QoL. In non-toxic goiter, improvements were observed in goiter symptoms, cosmetic complaints, anxiety, tiredness, and overall QoL. In toxic nodular goiter, significant improvements were observed in hyperthyroid and goiter symptoms and overall QoL, whereas several other domains did not change significantly. In hypothyroidism, significant improvements were observed in selected domains, including tiredness, impaired daily life, mood-related symptoms, and overall QoL. Analyses comparing ThyPRO scores between patient groups showed differences in selected domains; these comparisons were interpreted descriptively. Conclusion: Treatment was associated with improvements in QoL across the analyzed benign thyroid conditions, varying by disease group. Given the heterogeneity of the included studies and the absence of head-to-head comparisons of treatment efficacy across conditions, these findings should be interpreted descriptively. Disease-specific QoL assessment may help clinicians identify persistent symptom domains requiring attention during follow-up.

Cancer precision medicine is moving beyond static, single-analyte profiling toward a dynamic view of tumour biology and treatment response. A multiomics approach, integrating genomic, transcriptomic, proteomic, metabolomic, and epigenomic information, offers a more comprehensive framework for understanding tumour heterogeneity and therapeutic vulnerability. This review examines the emerging landscape of clinically available, translational, and experimental approaches, spanning commercially available platforms such as CureResponse and Exacta, single-cell and spatial technologies, AI-assisted plasma multiomics, and functional platforms including BH3 profiling and patient-derived organoid drug screening. We also discuss longitudinal liquid biopsy approaches for minimal residual disease assessment and recurrence monitoring. Together, these technologies may extend conventional biopsy by enabling increasingly multidimensional, spatially resolved, and longitudinal assessment of cancer. However, their clinical implementation remains limited by challenges in analytical standardisation, data integration, biological interpretation, validation, and demonstrated clinical utility. The convergence of multiomics, single-cell and spatial profiling, artificial intelligence, and functional testing is therefore reshaping precision oncology, from describing what a tumour is to predicting how it may behave and respond to treatment.